Trial Profile
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions; Registrational
- Acronyms RELY-ABLE
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 20 Jan 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 20 Nov 2013 Long-term pooled efficacy and safety analysis presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 23 Aug 2013 Additional data will be presented at the 2013 European Society of Cardiology (ESC) Congress, according to a Boehringer Ingelheim media release.